$4.63
-0.90 (-16.27%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where NTHI is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional
Held by 2 tracked-famous managers (MARSHALL WACE, LLP, Ancora Advisors LLC) · FINRA short interest 11.9 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisNCT06047379Phase 1: safety and tolerability of increasing dose levels of orally administered NEO212 alone in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or patients with select solid tumors with uncontrolled metastases to the brainNon-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib, Carboplatin, Paclitaxel, FOLFIRI Protocol, Bevacizumab | Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Solid Malignant Tumor, Microsatellite Instability-High Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma | 134 | 2027-02-28 | in 192 d | 2026-07-16 |
| NEO100 and High-Grade MeningiomaNCT05023018Progression free survival as six months (PFS6).Open-label · Treatment | Phase 2 | Recruiting | Drug: NEO100 | Residual, Progressive or Recurrent Grade II or III Meningioma | 30 | 2026-12-30 | in 132 d | 2026-07-16 |
| A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain TumorsNCT06357377Nature and severity of adverse eventsOpen-label · Treatment | Phase 1 | Not yet recruiting | Drug: NEO100 | Pediatric Tumor of CNS, Pediatric Tumor of Brain, Diffuse Midline Glioma, H3 K27M-Mutant, Pediatric Tumor of Brain Stem, Pineocytoma, Choroid Plexus Carcinoma, Childhood, Spinal Cord Tumor, High Grade Glioma | 12 | Oct 2026 | ≤ 72 d | 2026-01-14 |
| Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated GliomaNCT02704858Phase 1 Primary Outcome: Number of Participants with Abnormal Laboratory Values and/or Adverse Events That Are Related to TreatmentNon-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: Perillyl alcohol | Glioblastoma Multiforme | 49 | 2026-07-30 | — | 2026-07-16 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19